
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript March 20, 2025 ARS Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.52, expectations were $-0.04. Justin Chakma – Chief Business Officer: Richard Lowenthal – Co- …